Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies

Overview of attention for article published in Journal of Hematology & Oncology, March 2014

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (90th percentile)
High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

policy: 2 policy sources
twitter: 3 X users

guideline: 3 clinical guideline sources

Readers on

mendeley: 127 Mendeley

So far, Altmetric has seen 2 policy documents that reference this research output.

Adcetris for Hodgkin’s Lymphoma (post-ASCT) Resubmission – Details - Brentuximab (Adcetris) HL (post-ASCT) Resubmission – Final Clinical Guidance Report

Cited by Canadian Agency for Drugs and Technologies in Health (CADTH) on 10 Aug 2017

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma: Committee papers

Cited by National Institute for Health and Care Excellence (NICE) on 06 Mar 2017

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

This page shows the most recent policy documents that mention this research output. Click here to find out how to access more activity.